Bafna Pharmaceuticals Limited Bombay S.E.

BAFNAPH

INE878I01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-07-18 EDT			5-day change	1st Jan Change
86 ^INR	0.00%		-3.74%	-8.34%

06-29	Bafna Pharmaceuticals Limited Announces Temporary Disruption of Operations At Manufacturing Facility Situated At Grantlyon, Chennai	CI
05-29	Bafna Pharmaceuticals Limited Approves the Appointment of A. Mohanachandran as Company Secretary and Compliance Officer	CI

Bafna Pharmaceuticals Limited cancelled the transaction announced on June 17, 2016

January 03, 2017

On January 4, 2017, Bafna Pharmaceuticals Limited (BSE:532989) cancelled the transaction.

Latest news about Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited Announces Temporary Disruption of Operations At Manufacturing Facility Situated At Grantlyon, Chennai	06-29	CI
Bafna Pharmaceuticals Limited Approves the Appointment of A. Mohanachandran as Company Secretary and Compliance Officer	05-29	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-29	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-29	CI
Bafna Pharmaceuticals Limited Announces the Inauguration of New Quality Control Laboratory	04-26	CI
Bafna Pharmaceuticals Limited Announces Resignation of Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer	04-23	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India	12-10	MT
Bafna Pharmaceuticals Limited Announces Commercial Production	12-08	CI
Floods Disrupt Bafna Pharmaceuticals' Manufacturing Plant in Chennai, India	12-07	MT
Bafna Pharmaceuticals Limited Announces Suspension of Chennai Production Activity Due to Impact of Michaung Cyclone	12-07	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Bafna Pharmaceuticals Limited Announces Resignation of Kamlesh Kumar Babulal as Non-Executive Independent Director from the Board	23-09-23	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Bafna Pharmaceuticals Limited Approves Board Appointment	23-06-27	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-27	CI
Bafna Pharmaceuticals Limited Announces Appointment Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer	23-04-07	CI
Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-08	CI
Bafna Pharmaceuticals Limited Announces Resignation of Atul Sachdeva as Director	23-01-19	CI

Chart Bafna Pharmaceuticals Limited

Duration

Period

More charts

Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Companyâs subsidiary is Bafna Lifestyles Remedies Limited.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+26.58%	45.33B
OTSUKA HOLDINGS CO., LTD.	+38.49%	25.36B
SANDOZ GROUP AG	+27.75%	16.7B
CIPLA LIMITED	+20.89%	14.59B
ZYDUS LIFESCIENCES LIMITED	+72.03%	14.26B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.35%	6.67B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.62B
STADA ARZNEIMITTEL	-8.87%	5.73B